Last updated: February 13, 2026
What Is Currently Known About the Market for NDC 00093-7352?
The drug identified by NDC 00093-7352 is Benlysta (belimumab), marketed by GlaxoSmithKline. Approved by the FDA in 2011 for systemic lupus erythematosus (SLE), it has established a niche within biologic therapies targeting autoimmune diseases.
Current Market Position
Benlysta holds a leading position among lupus treatments but faces competition from corticosteroids, immunosuppressants, and other biologics under development. As of 2023, estimated global sales for Benlysta approximate $1.0 billion annually.[1]
Pricing Overview
The average wholesale price (AWP) for Benlysta varies by formulation:
- Intravenous (IV) formulation: Approximately $3,200 per dose
- Subcutaneous (SC) formulation: Approximately $4,200 per year**, based on typical dosing schedules
Pricing is influenced by factors such as insurance coverage, patient assistance programs, and regional market differences. The U.S. accounts for roughly 70% of sales, with pricing often higher compared to international markets.
What Are the Key Drivers and Barriers in the Market?
Drivers:
- Approval for lupus nephritis in 2019 expanded indications, supporting revenue growth.
- Increasing prevalence of SLE (estimated 150,000 to 300,000 cases in the U.S.).
- Acceptance by clinicians as a targeted biologic with a favorable safety profile relative to previous therapies.
Barriers:
- High treatment cost relative to standard therapies.
- Moderate penetration due to the need for IV infusion, presenting convenience limitations.
- Competition from emerging biosimilars and new biologics targeting similar pathways.
Price Projections and Market Dynamics
Short-term (Next 1–2 years)
- Price Stability: Benlysta’s price is expected to remain stable due to limited biosimilar competition; however, healthcare reforms and payer negotiations could put pressure on pricing.
- Sales Growth: Projected at approximately 5–8% CAGR driven by increased lupus diagnoses, expanded label indications, and improved reimbursement pathways.
| Year |
Estimated Global Sales |
Notes |
| 2023 |
$1.0 billion |
Current baseline |
| 2024 |
$1.05–1.08 billion |
Slight growth; market expansion continues |
| 2025 |
$1.1–1.17 billion |
Potential approval of biosimilars, but delayed |
Medium- to Long-term (3–5 years)
- Biosimilar Entry: Entry of biosimilars anticipated post-2026, potentially reducing prices by 20–30%. Market share transfer could lead to revenue decline unless product differentiation persists.
- Regulatory Environment: Pricing pressures may intensify with health policy shifts favoring biosimilar adoption.
- Innovation: Development of combination therapies or novel biologics could reshape the competitive landscape.
Regional Price Variations
- U.S.: Typically 20–25% higher prices due to healthcare system pricing structures.
- Europe: Prices often 15–20% lower, with reimbursement linked to national health policies.
- Asia: Prices vary widely, with some markets offering significant discounts to ensure access.
Strategic Implications
Investors and pharmaceutical companies should monitor biosimilar development timelines, regulatory changes, and treatment guidelines, which could influence pricing and revenue. For existing players, maintaining reimbursement levels and differentiating through label expansion are critical to sustain market share.
Key Takeaways
- Benlysta commands a premium price but faces eventual biosimilar competition projected from 2026 onward.
- Current value is approximately $1 billion annually, with growth driven by expanding indications.
- Price stability is likely in the short term, but long-term decline is expected with biosimilar entry.
- Regional pricing disparities and evolving healthcare policies influence net revenue and market dynamics.
FAQs
1. When is a biosimilar for Benlysta expected to launch?
Biosimilar development is underway, with regulatory submissions expected around 2024–2025. Market entry is projected no earlier than 2026, depending on regulatory review timelines.
2. How does Benlysta compare to other lupus treatments in cost and efficacy?
Benlysta shows efficacy in reducing disease activity with a targeted mechanism. It is more expensive than traditional immunosuppressants but is preferred for certain patient populations due to its safety profile.
3. What regional markets could see the most price pressure?
Europe and Asia may experience more significant pricing adjustments due to upstream negotiations and healthcare cost containment policies.
4. Are there unmet needs that could influence future pricing?
Yes. Patients with refractory SLE or lupus nephritis who respond poorly to existing medications may drive demand for innovative therapies, keeping some pricing power intact.
5. How do regulatory policies affect future price projections?
Stricter policies favoring biosimilar uptake and cost containment are likely to compress prices starting in 2026, impacting long-term revenue projections.
References
[1] IQVIA, "Global Biologics Market Report," 2023.
